Paroxysmal Cold Hemoglobinuria
Symptoms, Doctors, Treatments, Advances & More

Paroxysmal Cold Hemoglobinuria Overview

Save information for later
Sign Up

Learn About Paroxysmal Cold Hemoglobinuria

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Paroxysmal Cold Hemoglobinuria Local Doctors?
Elite in Paroxysmal Cold Hemoglobinuria
Pathology | Hematology | Oncology
Elite in Paroxysmal Cold Hemoglobinuria
Pathology | Hematology | Oncology

Sidney Kimmel Comprehensive Cancer Center

401 North Broadway Street, Weinberg BLDG, Weinberg BLDG, 
Baltimore, MD 
Languages Spoken:
English

Dr. Robert Brodsky is a professor of medicine at the Johns Hopkins University School of Medicine. His area of clinical expertise is classical hematology and haploidentical bone marrow transplant for sickle cell disease and aplastic anemia. Dr. Brodsky serves as the director of the Division of Hematology and the T32 Training Program. He is the Johns Hopkins Family Professor of Medicine and Oncology. He received his M.D. from Hahnemann University. He completed his residency at the Vanderbilt University School of Medicine. He performed a fellowship in hematology at the National Institutes of Health and a fellowship in oncology at Johns Hopkins. He joined the Johns Hopkins faculty in 1997. From 2017 to 2022 he served as Associate Editor to The Journal of Clinical Investigation (JCI) and Secretary to American Society of Hematology (ASH). He serves as President of The American Society of Hematology (ASH) in 2023. Dr. Brodsky is rated as an Elite provider by MediFind in the treatment of Paroxysmal Cold Hemoglobinuria. He is also highly rated in 29 other conditions, according to our data. His clinical expertise encompasses Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, Anemia, Bone Marrow Transplant, and Splenectomy. Dr. Brodsky is board certified in American Board Of Internal Medicine.

Elite in Paroxysmal Cold Hemoglobinuria
Elite in Paroxysmal Cold Hemoglobinuria

Cleveland Clinic

8950 Euclid Ave, 
Cleveland, OH 
Languages Spoken:
English
Offers Telehealth

Jaroslaw Maciejewski is a Hematologist practicing medicine in Cleveland, Ohio. Dr. Maciejewski is rated as an Elite provider by MediFind in the treatment of Paroxysmal Cold Hemoglobinuria. He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Paroxysmal Nocturnal Hemoglobinuria (PNH), Aplastic Anemia, Paroxysmal Cold Hemoglobinuria, Bone Marrow Transplant, and Splenectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Paroxysmal Cold Hemoglobinuria
Hematology | Oncology
Elite in Paroxysmal Cold Hemoglobinuria
Hematology | Oncology

Office

Calais, ME 
Languages Spoken:
English

Phillip Scheinberg is a Hematologist and an Oncologist practicing medicine in Calais, Maine. Dr. Scheinberg is rated as an Elite provider by MediFind in the treatment of Paroxysmal Cold Hemoglobinuria. He is also highly rated in 7 other conditions, according to our data. His clinical expertise encompasses Aplastic Anemia, Anemia, Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, and Bone Marrow Transplant.

What are the latest Paroxysmal Cold Hemoglobinuria Clinical Trials?
An Open-label, Single-arm, Multicenter, Phase 3 Study to Assess Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric PNH Patients 2 to <18 Years of Age

Summary: The purpose of this open-label, single arm, multicenter, phase 3 study is to assess the pharmacokinetics of iptacopan in pediatric patients and to assess whether iptacopan is safe and well tolerated when used for the treatment of pediatric paroxysmal nocturnal hemoglobinuria (PNH) patients 2 to \< 18 years of age.

Match to trials
Find the right clinical trials for you in under a minute
Get started
REAL-CARE: Real-world Effectiveness of iptacopAn in itaLian Patients With Paroxysmal noCturnAl HemoglobinuRia: an Observational Study

Summary: This study evaluates iptacopan effectiveness and safety in routine clinical practice, with a focus on hematological response, transfusion avoidance, and patient-reported outcomes. The primary objective of the REAL-CARE study is to is to assess the long-term hematological response following iptacopan initiation. This will be assessed through the absolute change in hemoglobin (Hb) levels at 12 month...